Patent-pending medical imaging research
What the standard scan misses.
QuietStorm™ BioTech, SPARK's patent-pending imaging research platform, is measuring changes in brain tissue that standard imaging misses, including signs consistent with the shear injury behind traumatic brain injury. We're looking for medical and research institutions to validate it independently. For research use only.
- 01
Seeing what images miss
Measures changes in brain tissue that standard MRI reads don't show, from scans that already exist.
- 02
Deterministic
No machine-learning training data. The same scan gives the same result, every time.
- 03
Ready for independent validation
We're inviting medical and research institutions to test it, blind, on their own data.
The problem
A normal-looking scan isn't always a normal brain.
People with real brain injuries routinely hear that their scans look normal. The damage is there, but it's too subtle and too diffuse for the image to show.
Subtle injury hides in plain sight
Diffuse injury is too small and too widespread for a standard read to catch, so the scan comes back normal.
Image-trained AI shares the blind spot
Models trained on standard images miss what those images miss, and they need large labeled datasets to learn at all.
No objective measure of recovery
Without a reliable measure, judgments of injury and recovery rest on symptoms and rating scales that change slowly and vary between assessors.
What we're seeing
We see something the standard image doesn't, and it matches what the science predicts.
Across several research datasets, QuietStorm BioTech is measuring changes that line up with what's known about each condition, in scans where the standard picture shows little or nothing.
Traumatic brain injury
Shear injury where the scan reads normal.
Standard imaging
Conventional MRI often looks normal after concussion and diffuse brain injury.
What we see
Changes along white-matter pathways consistent with the shearing injury known to underlie traumatic brain injury, clearly separating injured patients from healthy controls in a research cohort.
Why it matters
An objective measure of an often-invisible injury opens a new way to triage brain injury, track recovery, and study treatments, from the clinic to the battlefield.
Brain health & aging
Change measured before symptoms appear.
Standard imaging
Early change in the aging brain is invisible until atrophy or symptoms appear.
What we see
Steady, measurable change across the adult lifespan that also tracked cognitive performance in people whose clinical scores were still normal.
Why it matters
A measure that moves before symptoms do is what prevention research and early-intervention trials need.
Neurodegeneration research
Tissue measures that track clinical severity.
Standard imaging
Clinical rating scales are the main measure of disease progression.
What we see
In a neurodegenerative-disease research cohort, measures in deep brain structures tracked closely with clinical severity ratings.
Why it matters
Objective, repeatable measures are what trials need to see sooner whether a therapy is working.
Focal lesion research
Sharp contrast where the read is uncertain.
Standard imaging
Standard scoring rates some focal findings as indeterminate, leaving the next step uncertain.
What we see
Lesion tissue separated sharply from surrounding tissue within the same patient, including in cases standard scoring leaves indeterminate.
Why it matters
Better information at the point of uncertainty is a question worth testing prospectively with clinical partners.
These findings come from retrospective research analyses of existing de-identified datasets. No one has independently validated them yet; that is exactly what we are looking for partners to do. For research use only; not for diagnostic or clinical use.
Quantitative, repeatable
Measure the tissue, not just the picture.
QuietStorm BioTech produces quantitative tissue maps and consistent scores from the scans you already acquire, so you can compare results across people and over time.
It needs no new hardware, adds no scan time, and never alters the original images or records.
Validation partners sought
Test it blind, on your own data.
The strongest proof is the one you run yourself. We'll analyze your scans without seeing the answers.
- Stage 01
You choose the cohort
Your institution selects de-identified scans whose diagnoses or outcomes you already know, under your data-use and ethics approvals.
- Stage 02
We analyze blind
QuietStorm BioTech analyzes the scans without access to diagnoses, outcomes, or group labels.
- Stage 03
You score the results
Your team compares our measures with the known diagnoses and outcomes, and owns the evaluation. We publish findings together on terms agreed at the start.
Who we're looking for
Partners who can put it to the test.
Academic Medical Centers
Neurology, radiology, and neuroscience groups with well-characterized imaging cohorts.
Military & Veterans Health
Brain-injury and blast-exposure research programs for service members and veterans.
Brain-Injury Research Programs
Concussion, sports, and trauma research groups tracking injury and recovery.
Biopharmaceutical Companies
Trial teams looking for objective, exploratory imaging endpoints.
Imaging Research Centers
Groups with well-characterized imaging data and the expertise to evaluate new measures.
Research Funders
Programs funding objective measures of brain injury and brain health.
Why it's different
Beyond image-based AI.
Help us prove it.
We're looking for academic medical centers, military and veterans health programs, and biopharmaceutical partners to validate QuietStorm BioTech independently, on their own data. For research use only; not for diagnostic or clinical use.